| P50 | author | Keiran S M Smalley | Q61525717 |
| | John Koomen | Q87787364 |
| | Ritin Sharma | Q89948643 |
| | Vernon K Sondak | Q100288223 |
| | Inna V Fedorenko | Q117275264 |
| P2093 | author name string | Paige T Spence | |
| P2860 | cites work | Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation | Q22011187 |
| | PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization | Q22011202 |
| | Regulation of stress-responsive mitogen-activated protein (MAP) kinase pathways by TAO2 | Q24291055 |
| | Nek4 regulates entry into replicative senescence and the response to DNA damage in human fibroblasts | Q24294537 |
| | The protein kinase complement of the human genome | Q24324497 |
| | Nek4 status differentially alters sensitivity to distinct microtubule poisons | Q24600436 |
| | A landscape of driver mutations in melanoma | Q24603357 |
| | Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src | Q24614033 |
| | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 |
| | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | WebGestalt: an integrated system for exploring gene sets in various biological contexts | Q24813284 |
| | Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond | Q27026323 |
| | Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma | Q27852990 |
| | Cancer statistics, 2013 | Q27860762 |
| | Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview | Q28145787 |
| | A protein deep sequencing evaluation of metastatic melanoma tissues | Q28546229 |
| | The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013 | Q28710185 |
| | MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification | Q29547200 |
| | Cancer statistics, 2016 | Q29547383 |
| | Patterns of somatic mutation in human cancer genomes | Q29547841 |
| | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 |
| | Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 |
| | COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 |
| | Andromeda: a peptide search engine integrated into the MaxQuant environment | Q29615816 |
| | Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion | Q29617359 |
| | RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 |
| | 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data | Q30578327 |
| | Iterative rank-order normalization of gene expression microarray data | Q30621240 |
| | Knockdown of PFTK1 Inhibits the Migration of Glioma Cells | Q38847276 |
| | Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer | Q38868671 |
| | Large-scale proteomic characterization of melanoma expressed proteins reveals nestin and vimentin as biomarkers that can potentially distinguish melanoma subtypes | Q38947248 |
| | Systematic evaluation of quantotypic peptides for targeted analysis of the human kinome. | Q38963283 |
| | Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells | Q38989539 |
| | Mass spectrometry based method to increase throughput for kinome analyses using ATP probes | Q39162483 |
| | Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States | Q39190004 |
| | Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 |
| | Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines | Q41235107 |
| | Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. | Q41752617 |
| | Crosstalk and signaling switches in mitogen-activated protein kinase cascades | Q41771446 |
| | Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion | Q42206973 |
| | Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree | Q42549566 |
| | Melanoma | Q57571848 |
| | Intertumoral heterogeneity of receptor-tyrosine kinases expression in human melanoma cell lines with different metastatic capabilities | Q72525567 |
| | Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis | Q33946905 |
| | Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. | Q34032640 |
| | The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms | Q34165045 |
| | Functional interrogation of the kinome using nucleotide acyl phosphates | Q34599227 |
| | The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. | Q34676833 |
| | Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models | Q34677194 |
| | PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression | Q34761941 |
| | Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma | Q34975272 |
| | ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma | Q34990555 |
| | A targeted quantitative proteomics strategy for global kinome profiling of cancer cells and tissues | Q35092533 |
| | In situ kinase profiling reveals functionally relevant properties of native kinases | Q35125012 |
| | EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma | Q35163679 |
| | Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype | Q35164121 |
| | Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma | Q35262625 |
| | Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. | Q35579916 |
| | Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect | Q35605096 |
| | A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells | Q35692123 |
| | PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion | Q35815916 |
| | Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. | Q36373537 |
| | Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells | Q36476849 |
| | Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. | Q36793719 |
| | BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling | Q37271732 |
| | Focal adhesion kinase and cancer | Q37395451 |
| | Signal integration by JNK and p38 MAPK pathways in cancer development | Q37560607 |
| | Integrated proteomic analysis of post-translational modifications by serial enrichment. | Q37618636 |
| | MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition | Q37626175 |
| | Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma | Q37641646 |
| | Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma | Q37660341 |
| | Dabrafenib therapy for advanced melanoma | Q38164679 |
| | Novel downstream molecular targets of SIRT1 in melanoma: a quantitative proteomics approach. | Q38477654 |
| | Survival of patients with advanced metastatic melanoma: The impact of novel therapies | Q38680472 |
| | Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer | Q38798475 |
| | PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer | Q38803141 |
| P433 | issue | 12 | |
| P1104 | number of pages | 14 | |
| P304 | page(s) | 4476-4489 | |
| P577 | publication date | 2016-11-17 | |
| P1433 | published in | Journal of Proteome Research | Q3186939 |
| P1476 | title | Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition | |
| P478 | volume | 15 | |